Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lowered its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 33.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 92,972 shares of the company’s stock after selling 45,890 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.06% of Denali Therapeutics worth $1,895,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DNLI. FMR LLC boosted its holdings in shares of Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Denali Therapeutics during the fourth quarter worth about $514,000. JPMorgan Chase & Co. boosted its stake in Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after buying an additional 14,324 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Denali Therapeutics by 13.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after buying an additional 149,939 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in Denali Therapeutics in the 3rd quarter valued at about $792,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Up 4.1 %

DNLI stock opened at $14.78 on Friday. The company has a market capitalization of $2.15 billion, a PE ratio of -5.36 and a beta of 1.46. The stock’s 50 day moving average is $19.05 and its two-hundred day moving average is $23.23. Denali Therapeutics Inc. has a 52-week low of $13.67 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. As a group, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Upgrades and Downgrades

DNLI has been the topic of several research analyst reports. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. HC Wainwright boosted their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Monday, December 16th. B. Riley reiterated a “buy” rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group dropped their price target on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.20.

Insider Transactions at Denali Therapeutics

In related news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the transaction, the director now owns 107,976 shares in the company, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is currently owned by corporate insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.